James Yu, MD
Radiation Oncology · Lebanon, NHNPI 1306020474
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $81,600 of the $111,734 with a category attached, or 73.0%. Boston Scientific accounts for 83.0% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $71,683 and has fallen 98.6% since, to $1,033 in 2025. Among radiation oncology clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 80 payments — averaging $1396.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$93K
- Augmenix, Inc.$8K
- Myovant Sciences Inc.$5K
- Pfizer$4K
- Reflexion Medical, Inc.$2K
- Teleflex LLC$462
- plus $264 from 6 others
Across 2 payments — averaging $128,438 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$257K
What the payments were for
- Consulting fees$22,77520%
- Speaking & faculty fees$81,60073%
- Travel & lodging$6,0375%
- Food & beverage$1,3221%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 64 | $92,733 |
| Augmenix, Inc. | 3 | $7,750 |
| Myovant Sciences Inc. | 2 | $4,949 |
| Pfizer | 1 | $3,500 |
| Reflexion Medical, Inc. | 2 | $2,075 |
| Teleflex LLC | 2 | $462 |
| Genmab U.S., Inc. | 1 | $127 |
| Bioprotect Medical, Inc. | 1 | $37 |
| Accuray Incorporated | 1 | $33 |
| Blue Earth Diagnostics | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Myriad Genetic Laboratories, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPACEOAR$45,909
- GENERAL BPH$34,813
- GENERAL - THERAPIES$12,228
- ORGOVYX$8,350
- SpaceOAR System$3,400
- SpaceOAR VUE System - 10mL$2,625
- REFLEXION MEDICAL RADIOTHERAPY SYSTEM$2,000
- Barrigel$350
- TIVDAK$127
- GENERAL ONCOLOGY$111
How this compares
$111,734 in reported general payments places this provider in the 95th percentile of 35 radiation oncology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 89 | $986 |
| Triamcinolone Acetonide | 12 | $44 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Lebanon
- Evangelia KatsoulakisLebanon$16K
- Kelly UnderhillLebanon$1K
- Nirav KapadiaLebanon$485
- Gregory RussoLebanon$383
- Bassem ZakiLebanon$360
- Katie LichterLebanon$142
- Thomas DelaneyLebanon$102
- Liza StaplefordLebanon$89
- Charles ThomasLebanon$22
- Lesley JarvisLebanon$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.